Damora Therapeutics, Inc. Common Stock
DMRAStock
$30.24
Market Cap$1.91B
P/E—
Div yield—
Beta-4.50
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)54.81%
VGM Score80.15
Market Capitalization$1.91B
Earnings Surprise History
Q1 26-0.62est. -0.40
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.25
4.31
4.27
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DMRADamora Therapeutics, Inc. Common Stock | — | — | A | $30.24 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Damora Therapeutics develops biologics for calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant unmet medical need for disease-modifying treatments. The company's pipeline includes DMR-001, DMR-002, DMR-003, and GB3226, designed to provide broad mutation coverage in hematologic disorders.